E R Dorsey

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. doi Knowledge of the Genetic Information Nondiscrimination act among individuals affected by Huntington disease
    E R Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, MD, USA
    Clin Genet 84:251-7. 2013
  2. pmc Randomized controlled clinical trial of "virtual house calls" for Parkinson disease
    E Ray Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, MD 21287, USA
    JAMA Neurol 70:565-70. 2013
  3. pmc The coming crisis: obtaining care for the growing burden of neurodegenerative conditions
    E Ray Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, MD, USA
    Neurology 80:1989-96. 2013
  4. pmc Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study
    E Ray Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 7:e29522. 2012
  5. doi Commentary: improving the supply and distribution of primary care physicians
    E Ray Dorsey
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Acad Med 86:541-3. 2011
  6. pmc Group patient visits for Parkinson disease: a randomized feasibility trial
    E R Dorsey
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Neurology 76:1542-7. 2011
  7. pmc Quantitative risk-benefit analysis of natalizumab
    J P Thompson
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Neurology 71:357-64. 2008
  8. ncbi Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10
    K M Biglan
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    J Huntingtons Dis 1:65-9. 2012
  9. ncbi Communicating clinical trial results to research participants
    E Ray Dorsey
    Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Ave, Ste 223, Rochester, NY 14620, USA
    Arch Neurol 65:1590-5. 2008
  10. pmc Selegiline shortage: Causes and costs of a generic drug shortage
    E R Dorsey
    Department of Neurology, University at Buffalo, NY, USA
    Neurology 73:213-7. 2009

Detail Information

Publications12

  1. doi Knowledge of the Genetic Information Nondiscrimination act among individuals affected by Huntington disease
    E R Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, MD, USA
    Clin Genet 84:251-7. 2013
    ..Thus, among individuals affected by HD, familiarity with and knowledge of GINA are low. The effectiveness of the legislation may be limited by this lack of knowledge. ..
  2. pmc Randomized controlled clinical trial of "virtual house calls" for Parkinson disease
    E Ray Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, MD 21287, USA
    JAMA Neurol 70:565-70. 2013
    ..The burden of neurological disorders is increasing, but access to care is limited. Providing specialty care to patients via telemedicine could help alleviate this growing problem...
  3. pmc The coming crisis: obtaining care for the growing burden of neurodegenerative conditions
    E Ray Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, MD, USA
    Neurology 80:1989-96. 2013
    ..Rather than guaranteeing access to care, Medicare's reimbursement policies may increasingly be an impediment to care...
  4. pmc Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study
    E Ray Dorsey
    Department of Neurology, Johns Hopkins Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 7:e29522. 2012
    ..Careful characterization of the phenotype and genotype of Huntington disease (HD) can foster better understanding of the condition...
  5. doi Commentary: improving the supply and distribution of primary care physicians
    E Ray Dorsey
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Acad Med 86:541-3. 2011
    ....
  6. pmc Group patient visits for Parkinson disease: a randomized feasibility trial
    E R Dorsey
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Neurology 76:1542-7. 2011
    ..This care delivery method has demonstrated benefits for individuals with chronic conditions but has not been evaluated for Parkinson disease (PD)...
  7. pmc Quantitative risk-benefit analysis of natalizumab
    J P Thompson
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Neurology 71:357-64. 2008
    ..To model the long-term risks and benefits of natalizumab in individuals with relapsing multiple sclerosis (MS)...
  8. ncbi Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10
    K M Biglan
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    J Huntingtons Dis 1:65-9. 2012
    ..19.5 ± 4.7 pg/ml, p = 0.87) though baseline CoQ levels were elevated in HD compared with controls (p < 0.001). CoQ treatment reduces plasma 8OHdG and this reduction may serve as a marker of pharmacologic activity of CoQ in HD. ..
  9. ncbi Communicating clinical trial results to research participants
    E Ray Dorsey
    Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Ave, Ste 223, Rochester, NY 14620, USA
    Arch Neurol 65:1590-5. 2008
    ..Communicating clinical trial results to research participants is seldom accomplished in a timely or an effective manner...
  10. pmc Selegiline shortage: Causes and costs of a generic drug shortage
    E R Dorsey
    Department of Neurology, University at Buffalo, NY, USA
    Neurology 73:213-7. 2009
    ..We sought to evaluate prescription trends of generic selegiline and to quantify the economic impact of any resulting drug substitution of more expensive alternatives...
  11. ncbi Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis
    E R Dorsey
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
    Neurology 68:1524-8. 2007
    ..033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days)...
  12. ncbi Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
    E R Dorsey
    Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Blvd, Suite 223, Rochester, NY 14620, USA
    Neurology 68:384-6. 2007
    ..The number of individuals with PD over age 50 in these countries was between 4.1 and 4.6 million in 2005 and will double to between 8.7 and 9.3 million by 2030...